We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsAnthony @ Equity Investigations, Dear Anthony,

Previous 10 Next 10 
To: straight-->arrow who wrote (116415)5/24/2013 3:07:35 PM
From: StockDung
   of 122044
Straight-> arrow, why was Jeffery McAnally referred to as being a DR? Is he a DR? Does he have a PH.D?

In the article you posted he is not called "Dr".

Why is this? Can you explain? This article was from 2004

The key ingredients of Macular Health's Dry Eye Formula are borage seed oil, flaxseed oil and Omega-3 fish oil.

Smells fishy!!
Alabama Doctor Introduces Pill to Prevent Vision Loss

By: Courtney Hayes
Updated: Mon 2:06 PM, Jun 21, 2004

An Alabama doctor is introducing a new vitamin to local doctors that helps decrease the risk of vision loss.

Dr. Jeffery McAnally created "macular health", after watching many of his patients go blind because of age-related macular degeneration. The small pill is taken once a day, and contains four important nutrients that most of the common over-the-counter vitamins do not.

Dr. McAnally says it's that improved formula that has helped one of his patients go from legally blind to driving a car.

"It's based on a ten-year study. We basically mimicked that study, but also added other ingredients that were not available at the time of the study; like lutein, bilberry and Zeaxanthin. We put it in a small pill taken once a day, which is much easier for seniors who are already taking handfuls of pills a day anyways," says Dr. Jeffery McAnnally.

If you like to find out more about "macular health" log onto Extended Web Coverage

Adult Macular Degeneration

Adult macular degeneration is traditionally described as that form of the disease that affects individuals over the age of 55 years. However, we have recently discovered that a significant number of these individuals may have a major genetic component that contributes to the disease.

What does macular degeneration do to your vision?

Your retina contains an extraordinary photosensitive array of cells that line the back of your eye. The light falling onto these cells in the retina is transformed into electrical signals which are transmitted to the brain centers that process and interpret them.

The most concentrated collection of photosensitive cells in your retina, including those that enable critical color and fine detail vision, are found in the Bulls-Eye center zone in an area called the macula.

Macular degeneration is the imprecise historical name given to that group of diseases that causes sight-sensing cells in the macular zone of the retina to malfunction or lose function and results in debilitating loss of vital central or detail vision.

Because the brain cleverly learns to compensate and fill in the missing part of the picture in early cases with spotty macular cell damage or dysfunction, most people only present to their ophthalmologist when disease is fairly advanced. Compared to the huge numbers of people affected (over 12 million), research efforts toward discovery of cause and cure by government, public and private institutions are inappropriately small.

What are the Symptoms of Macular Degeneration?

Macular degeneration can cause different symptoms in different people. Sometimes only one eye loses vision while the other eye continues to see well for many years. The condition may be hardly noticeable in its early stages, but when both eyes are affected, reading and close up work can become difficult.

If you have been diagnosed with adult macular degeneration you are in good company. Another case of adult macular degeneration is diagnosed every three minutes in the United States of America. One in six Americans between the ages of 55 and 64 will be affected while one in four Americans between 64 and 74 will be smitten. One in three over the age of 75 will be affected. Each year 1.2 million of the estimated 12 million people with macular degeneration will suffer severe central vision loss.

Each year 200,000 individuals will lose all central vision in one or both eyes. While the causes of macular degeneration are unknown, some tantalizing clues have become available. Genetic researchers, supported in part by the Macular Degeneration Foundation, have recently discovered a group of genes termed ABCR.

Possession of these genes may increase the likelihood of an individual developing macular degeneration by approximately 30 percent. However, most macular diseases have a complex genetic makeup compared with single gene-causation diseases. In most individuals macular degeneration is likely due to both environmental and genetic factors that combine to cause damage and disease.

Genetic typing of patients with macular degeneration is likely to assume more and more importance in the future. It will enable ophthalmologists to identify high-risk individuals and to better understand the relationships between genetic defects, the appearance of the macula and how the disease progresses. This information will hopefully provide scientists with some of the tools they need to develop therapies that can prevent, slow and even arrest the progression of macular degeneration.

What can you or your loved one do if diagnosed with macular degeneration?

First it is important to modify those environmental risk factors that we know about.

You should:
  1. Detail a low-fat, low cholesterol diet.

  2. If you are post menopausal, you should consult with your physician concerning estrogen replacement therapy. This may have a favorable impact upon cholesterol lipid levels that play a role in worsening the disease.

  3. Wear sunglasses with UV protection.

  4. Try to consume at least two servings of leafy dark green vegetables per day.

  5. Do not smoke and avoid exposure to secondhand smoke.

  6. Eat food and or supplements rich in vitamin E,C and Lutein. Lutein is a plant antioxidant found in high quantities in spinach, kale and other dark green, leafy vegetables.

Some emerging theories about what may play a role in causing or worsening macular degeneration are as follows:

  1. The macular contains many highly active and sensitive photoreceptors that require and consume a great deal of energy. Generating this energy requires a constant, rich supply of oxygen, nutrients and ions. Consequently, the macula has one of the highest rate of blood flow through its supply vessels. Anything that interferes with this necessary rich blood supply can cause the macula to malfunction and possibly become diseased.

  2. Smoking can reduce this vital blood supply by contributing to narrowing of the blood vessels and thickening of the blood, as it does in the heart and brain where this process contributes to heart attacks and strokes.

  3. A high-fat, high cholesterol diet can lead to fatty plaque deposition in the macular vessels hampering blood flow.

  4. A shortage of antioxidants may also increase the tendency for fatty deposits to stick to blood vessel walls.

Source: Macular Degeneration Foundation (

Share RecommendKeepReplyMark as Last Read

To: straight-->arrow who wrote (116415)5/24/2013 3:13:15 PM
From: StockDung
   of 122044
A large shareholder of Fuse Science is Danny Garber

He was involved with Roy Ageloff

Does Tiger Woods know this?

12/16/96 THE MOB ON WALL STREET--PART 1 - Businessweek

Jun 14, 1997 – A trader at Naib Trading Corp. in Fort Lauderdale was summoned to the office of a man by the name of Roy Ageloff. The trader has told ...

Share RecommendKeepReplyMark as Last Read

To: straight-->arrow who wrote (116415)5/24/2013 3:32:11 PM
From: StockDung
   of 122044
Lets hope Tiger Woods is not the third party that paid this unscroupulous penny stock promoter SHAZAM!! stocks to promote Fuse Science.

Share RecommendKeepReplyMark as Last Read

To: straight-->arrow who wrote (116415)5/24/2013 3:37:40 PM
From: StockDung
   of 122044
wow Kenneth Yellin who is in Fuse Science filing and was charged with Securities fraud currently is under a criminal investigation into kickbacks also

Probe Into NIR Group Expanded [ View article

That's a good question why WSJ is doing it now. Here is what I found:

Former Senior analyst Daryl Dworkin and Former Vice President of the NIR Group team Kenneth D. Yellin are the subject of an ongoing criminal probe sources close to the matter say.

Federal Prosecutors have uncovered what is believed to be a kickback scheme that Dworkin and Yellin had going for several years. The sources say that the Wall Street Journal has incorrectly reported the potential charges and scope of the investigation.

Dworkin and Yellin both highly paid executives while at NIR have reportedly pocketed an indeterminate amount of cash and lavish gifts.

According to several key witnesses in the investigation, former employees and others who have been spoken to by prosecutors and the FBI say founder Corey Ribotsky was not aware of the kickback scheme and did not take part in it.

While NIR has been the subject of an ongoing probe into numerous accusations, no wrongdoing has been found and no charges have been filed.

Sources close to the investigation say Mr Ribotsky himself voluntarily went in to speak to regulators and prosecutors in an effort to show there was no wrong doing on his part or his firm.

The Wall Street Journal incorrectly states as well that independent valuations for the firm's PIPE investment funds have not been completely. We have learned that valuations for these investments have been completed and received.

Belive it or not, it starts to become interesting here.
Mar 3 12:18 PM | 0 Likes

Share RecommendKeepReplyMark as Last Read

To: straight-->arrow who wrote (116415)5/24/2013 3:48:09 PM
From: StockDung
   of 122044
So Straight. Name the CRIMMs in Fuse Science SEC filings.

SEC Charges Four Penny Stock Purchasers with Fraud
Washington, D.C., Dec. 21, 2012 — The Securities and Exchange Commission today charged four securities industry professionals with conducting a fraudulent penny stock scheme in which they illegally acquired more than one billion unregistered shares in microcap companies at deep discounts and then dumped them on the market for approximately $17 million in illicit profits while claiming bogus exemptions from the federal securities laws.

Additional Materials
SEC Complaint

The SEC alleges that Danny Garber, Michael Manis, Kenneth Yellin, and Jordan Feinstein acquired shares at about 30 to 60 percent off the market price by misrepresenting to the penny stock companies that they intended to hold the shares for investment purposes rather than immediately re-selling them. Instead, they immediately sold the shares without registering them by purporting to rely on an exemption for transactions that are in compliance with certain types of state law exemptions. However, no such state law exemptions were applicable to their transactions. To create the appearance that the claimed exemption was valid, they created virtual corporate presences in Minnesota, Texas, and Delaware. The SEC also charged 12 entities that they operated in connection with the scheme.
According to the SEC’s complaint filed in federal court in Manhattan, Garber, Manis, Yellin, and Feinstein all live in the New York/New Jersey area and operated the scheme from 2007 to 2010. They each have previously worked in the securities industry either as registered representatives or providers of investment management or financial advisory services.
“These penny stock purchasers had enough securities industry experience to know that their penny stock trading was not exempt from the securities laws as they claimed,” said Andrew M. Calamari, Director of the SEC’s New York Regional Office. “They repeatedly violated the registration provisions and in the process also committed securities fraud. We will continue to fight microcap stock abuses that result in the unregistered distribution of shares without vital information about those companies being known to investors.”
The SEC’s complaint alleges that Garber, Manis, Yellin, Feinstein and the named entities violated Sections 5(a), 5(c), and 17(a) of the Securities Act of 1933; Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The SEC’s complaint seeks a final judgment, among other things, ordering all of the defendants to pay disgorgement, prejudgment interest and financial penalties; permanently enjoining all the defendants from future violations of the securities laws; and permanently enjoining all the defendants from participating in penny stock offerings.
The SEC’s investigation, which is continuing, has been conducted by Michael Paley, Laura Yeu, Elzbieta Wraga, Haimavathi Marlier, Yitzchok Klug and Paul Gizzi of the New York Regional Office. Mr. Gizzi and Ms. Marlier will lead the SEC’s litigation.
# # #

Share RecommendKeepReplyMark as Last Read

To: straight-->arrow who wrote (116415)5/24/2013 3:59:46 PM
From: StockDung
   of 122044
All four own warrants in the Fuse SEC filing

The SEC alleges that Danny Garber, Michael Manis, Kenneth Yellin, and Jordan Feinstein

Share RecommendKeepReplyMark as Last Read

From: StockDung5/25/2013 10:01:21 AM
   of 122044
Dick Davis still promoting serial fraudtser Geoffey Eiten

Share RecommendKeepReplyMark as Last Read

From: StockDung5/25/2013 10:04:06 AM
   of 122044
You can still discuss your investments with serial fraudster Geoffrey Eiten

Get Started Today!
Subscribe Here!
OTC Research Corporation’s monthly newsletters give you solid results, a unique consulting service, and a 100% money-back guarantee on all unsent issues.

Keep in mind that, with your paid subscription to OTC Growth Stock Watch, in addition to receiving a top-rated newsletter, you automatically qualify for the following benefits:

  • Discuss your investments directly with Publisher and Chief Analyst Geoffrey Eiten and benefit from his extensive experience in following growth stocks. Mr. Eiten’s analytical skills are an invaluable asset to any investor. Many of our customers feel that the personal access to Mr. Eiten is alone worth the price of their subscriptions and greatly enhances the value of the newsletters.
  • Avoid "snail-mail" and get your monthly growth stock advice with our fast circulation alternatives. OTC Growth Stock Watch is also available via electronic mail to guarantee timely delivery of the information!
OTC GSW is a monthly newsletter focusing on featuring growth stocks and, as such, is competitively priced in its specialty market. Mr. Eiten also regularly authorizes various special offers and promotions.

Subscribing is quick and easy. Use our online form to subscribe with your credit card. You may also print out and mail the form with your check payment to:

OTC Research Corporation
PO Box 715
Dover, MA 02030

You may also call us at 781-444-6100, and subscribe over the phone using your MasterCard, Visa, Discover (American Express coming soon)

However you subscribe, you may wish to "auto-renew" your subscription, using your credit card. Then, when your subscription is up for renewal, you won’t be bothered by renewal notices or experience inconvenient lapses in your delivery.

We are convinced that you will be pleased with our monthly newsletters. However, if you are not 100% satisfied with your subscription, you have our special Money-Back Guarantee: at any time during the remainder of your subscription you may receive a COMPLETE REFUND ON YOUR UNSENT ISSUES.

If you still doubt whether to sign up, read what our current and past subscribers have said about the monthly newsletters.

Exciting investment opportunities await you! Make a sound investment today for greater returns tomorrow. Subscribe to OTC Growth Stock Watch to OTC Growth Stock Watch to receive your FREE OTC Special Situations bonus reports.

Subscribe Here!

[ Home ] [ GSW ] [ Publisher ] [ Subscription Info ]

© 2008, OTC Research Corporation
All rights reserved.
Privacy Policy

Share RecommendKeepReplyMark as Last Read

From: StockDung5/25/2013 10:53:37 AM
   of 122044
No InterOil delivery could burn Paulson

By KAJA WHITEHOUSE Last Updated: 12:27 AM, May 25, 2013 Posted: 10:47 PM, May 24, 2013

    While he’s still licking his wounds from the Sino-Forest scandal, hedge-fund titan John Paulson has waded into another controversial stock.

    The founder of $18 billion Paulson & Co. scooped up 1.87 million shares of InterOil Corp. in the first quarter, making him the company’s eighth-largest shareholder, with a stake worth roughly $160 million.

    InterOil has been touting its access to oil and natural gas reserves in Papua New Guinea, but has yet to extract them — kicking off a Wall Street debate as to the veracity of its claims.

    InterOil’s stock has risen 60 percent this year after the company raised hopes that a long-awaited deal to develop its natural gas fields was finally at hand.

    Stock aflame: Shares of IOC, which boasts access to oil and gas reserves, have soared 60 percent this year, enriching hedgie John Paulson, a big stakeholder in the company.

    But a sudden drop in the stock yesterday raised fresh questions about whether the upward trend will continue, or whether InterOil naysayers will be proven right and the stock will collapse.

    “If I am correct, there are no commercially developable resources and this is the beginning of the end,” said hedge fund manager Whitney Tilson, who is short the stock.

    In March, InterOil said it received multiple bids from partners eager to get in on its natural gas action. The news sent the stock soaring on speculation that the company would be acquired by a major energy company.

    But critics scoffed at news of the bids, attributing it to InterOil’s practice of churning out promising press releases and then failing to deliver.

    Short sellers like Tilson got a boost yesterday when InterOil said it had entered into “exclusive negotiations with ExxonMobil Papua New Guinea Ltd.”

    The stock soared to $106 before plummeting back down again, when investors realized the deal was far from done. It ended the day off 7.5 percent at $86.40.

    InterOil spokesman Wayne Andrews didn’t return a request for comment.

    Paulson, who also declined to comment, has found himself on the losing side of a similar debate.

    In 2011, his firm lost an estimated $700 million betting on Chinese operated Sino-Forest, which collapsed amid an accounting scandal.

    Share RecommendKeepReplyMark as Last Read

    To: straight-->arrow who wrote (116415)5/25/2013 12:17:54 PM
    From: StockDung
       of 122044
    FUSE promoted by Tiger Woods and big Weiner!! They where expecting big things from Weiner but FUSE ended up getting slapped by Weiner. A BIG WEINER stock promotion!!

    Lets hope Tiger Woods is not the third party that paid this unscroupulous penny stock Weiner SHAZAM!! stocks to promote Fuse Science.


    Detail by Entity Name
    Florida Profit Corporation
    Filing Information
    Document NumberP05000006222
    FEI/EIN Number061738910
    Date Filed01/12/2005
    State or CountryFL

    Principal Address
    10611 KEYSTONE CT
    WELLINGTON, FL 33414

    Changed: 08/16/2006
    Mailing Address
    10611 KEYSTONE CT
    WELLINGTON, FL 33414

    Changed: 08/16/2006

    Registered Agent Name & Address
    WELLINGTON, FL 33414

    Name Changed: 08/16/2006

    Address Changed: 08/16/2006
    Officer/Director Detail
    Name & Address

    Title P

    WELLINGTON, FL 33414

    Annual Reports
    Report Year Filed Date
    2011 04/07/2011
    2012 04/10/2012
    2013 03/30/2013

    Document Images
    03/30/2013 -- ANNUAL REPORT View image in PDF format
    04/10/2012 -- ANNUAL REPORT View image in PDF format
    04/07/2011 -- ANNUAL REPORT View image in PDF format
    03/24/2010 -- ANNUAL REPORT View image in PDF format
    06/15/2009 -- ANNUAL REPORT View image in PDF format
    04/24/2008 -- ANNUAL REPORT View image in PDF format
    07/17/2007 -- ANNUAL REPORT View image in PDF format
    08/16/2006 -- ANNUAL REPORT View image in PDF format
    01/12/2005 -- Domestic Profit View image in PDF format

    Share RecommendKeepReplyMark as Last ReadRead Replies (1)
    Previous 10 Next 10